Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 410.98 15.80
P/S ratio
1.92 2.43 2.64 3.31
P/FCF ratio
21.00 32.79 37.30 10.75
P/Operating CF
16.85 28.60 28.67 36.64
P/B ratio
2.02 2.40 2.58 3.17
EV/Sales
2.72 3.11 3.20 3.78
EV/EBITDA
59.08 49.93 21.01 10.76
EV/FCF
29.70 42.02 45.21 12.27
Current Ratio
1.65 1.86 2.04 1.78
Net Debt/EBITDA
14.06 6.72 4.79 5.04
Debt/Equity
1.35 1.24 1.18 0.91
Earnings Yield
(4.52%) (3.41%) 0.24% 6.33%
Free Cash Flow Yield
4.76% 3.05% 2.68% 9.30%
Free Cash Flow per Share
6.38 5.26 6.28 5.07
Book value per Share
65.23 70.82 73.22 75.98
Free Cash Flow
386.98 320.46 388.50 320.60
EV/EBIT
0.00 0.00 0.00 19.38
Other line items

Show all line items

Columns are period end dates